Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis.

Article Details

Citation

Copy to clipboard

Ko MW, Tamhankar MA, Volpe NJ, Porter D, McGrath C, Galetta SL

Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis.

J Neurol Sci. 2008 Oct 15;273(1-2):144-7. doi: 10.1016/j.jns.2008.06.028. Epub 2008 Aug 6.

PubMed ID

18687447 [ View in PubMed

]

Abstract

Mitoxantrone, the first immunosuppressant to receive FDA approval for treatment of worsening relapsing-remitting, secondary progressive, and progressive-relapsing multiple sclerosis (MS) is a DNA topoisomerase II inhibitor that has been associated with the development of acute promyelocytic myelogenous leukemia (APML). Central nervous system APML is a rare site of extramedullary involvement following mitoxantrone therapy. We report a patient with history of multiple sclerosis who developed bilateral optic nerve involvement as the primary manifestation of APML relapse following mitoxantrone treatment.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Mitoxantrone	DNA topoisomerase 2-alpha	Protein	Humans	Yes	Inhibitor	Details